Aguilar-Olivos N, Motola-Kuba M, Briones-Torres CA, Lizardi-Cervera J, Méndez-Sánchez N, Uribe M

Language: Spanish
References: 10
Page: 156-159
PDF size: 65.85 Kb.

ABSTRACT

Background: In patients with chronic HCV, it has been described the single nucleotide polymorphism (SNP) rs12979860 IL-28B as an important response predictor to the treatment with ribavirin and pegylated interferon alpha. CC polymorphism carriers have ratios > 80% of sustained viral response (SVR). Patients with TT polymorphism have lower rates of SVR with 40% of treatment response and CT polymorphism has intermediate SVR rates. Objective. To determine the distribution of interleukin 28B (IL-28B) rs12979860 polymorphisms in patients with chronic hepatitis C virus (HCV) studied at Fundación Clínica Médica Sur. Material and methods. A retrospective and descriptive study was developed at Fundación Clínica Médica Sur to determine the distribution of genotypes of IL- 28B rs12979860 in patients with chronic HCV. It was collected and analyzed the results of the IL-28B polymorphism rs12979860, demographic, clinical and virological features. Results. 59 determinations of IL-28B genotype of rs12979860 were performed from March 2011 to December 2012. The analysis showed 25% (15/59) of CC, 51% (30/59) of CT and 24% (14/59) of TT polymorphisms. Conclusions. The population studied showed a high percentage of polymorphisms associated with lower rates of SVR to interferon and ribavirin. The CC was only found in 25% of patients.

REFERENCES

1. Thomas DL, Astemborski J, Rai RM, Anania FA, Schaeffer M, Galai N, Nolt K, et al. The natural history of hepatitis C virus infection: host, viral, and environmental factors. JAMA 2000; 284(4): 450-6.

2. Thomas DL, Seeff LB. Natural history of hepatitis C. Clin Liver Dis 2005; 9(3): 383-98.

3. Chen SL, Morgan TR. The natural history of hepatitis C virus (HCV) infection. Int J Med Sci 2006; 3(2): 47-52.

4. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Management of hepatitis C virus infection. J Hepatol 2011; 55(2): 245-64.

5. Ghany MG, Strader DB, Thomas DL, Seeff LB; American Association for the Study of Liver Diseases. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009; 49(4): 1335-74.

6. Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, Urban TJ, Heinzen EL, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009; 461(7262): 399-401.

7. Balagopal A, Thomas DL, Thio CL. IL28B and the control of hepatitis C virus infection. Gastroenterology 2010; 139(6): 1865-76.

8. Stättermayer AF, Stauber R, Hofer H, Rutter K, Beinhardt S, Scherzer TM, Zinober K, et al. Impact of IL28B genotype on the early and sustained virologic response in treatment-naïve patients with chronic hepatitis C. Clin Gastroenterol Hepatol 2011; 9(4): 344-50.

9. Sixtos-Alonso MS, Ávalos Martínez R, Dehesa-Violante M, Sandoval- Salas R, García Juárez I, Chávez Ayala A, et al. Distribution of RS12979860 IL28B gene polymorphism in mexican patients with chronic HCV infection. Ann Hepatol 2011; 10(3): 382-411.

10. Martínez-Gómez LE, Chávez-Tapia NC, Burguete-García AI, Aguilar- Olivos N, Madrid-Marina V, Román-Bahena M, Orbe-Orihuela C, et al. IL28B polymorphisms predict the response to chronic hepatitis C virus infection treatment in a Mexican population. Ann Hepatol 2012; 11(6): 876-81.